

# EXHIBIT C

# GENEVANT

October 12, 2021

BY FEDERAL EXPRESS

Michael P. Bauer, Ph.D.  
Assistant General Counsel  
Pfizer, Inc.  
235 East 42<sup>nd</sup> Street  
New York, New York 10017


**Re: Arbutus/Genevant LNP Technology and Intellectual Property**

Dear Mr. Bauer:

Thank you for your October 7, 2021, email to Pete Zorn informing Genevant that BioNTech will be handling further discussions regarding a potential license relating to COVID-19 vaccines. We look forward to hearing from BioNTech.

In the meantime, we believe, and notify Pfizer and BioNTech under 35 U.S.C. § 287(a), that the manufacture, importation, offer for sale, sale, and/or use of the Pfizer-BioNTech COVID-19 vaccine Comirnaty® may infringe Arbutus U.S. Patent No. 11,141,378, in addition to at least the Arbutus patents that were identified in our November 23, 2020 letter.

Sincerely,



Markus Rohrwild  
Managing Director  
Genevant Sciences GmbH  
Viaduktstrasse 8, 4051  
Basel, Switzerland



William H. Collier  
President and Chief Executive Officer  
Arbutus Biopharma Corporation  
701 Veterans Circle  
Warminster, Pennsylvania 18974 USA

Cc: Ugur Sahin  
Chief Executive Officer  
BioNTech SE  
An der Goldgrube 12  
D-5131 Mainz Germany

Albert Bourla, DVM, Ph.D.  
Chairman and Chief Executive Officer  
Pfizer, Inc.  
235 East 42<sup>nd</sup> Street  
New York, New York 10017 USA

Sierk Poetting  
Chief Financial Officer and Chief  
Operating Officer  
BioNTech SE  
An der Goldgrube 12  
D-55131 Mainz Germany

Doug Lankler, Esq.  
Executive Vice President, General Counsel  
Pfizer, Inc.  
235 East 42<sup>nd</sup> Street  
New York, New York 10017 USA

General Counsel  
BioNTech US Inc.  
40 Erie Street, Suite 110  
Cambridge, MA 02139 USA

10298-00001/12998850.1